Brokerage Firm Rating Update on BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) : 11 brokerage houses believe that BioMarin Pharmaceutical (BMRN) is a Strong Buy at current levels. 2 Analyst considers the fundamentals to be worthy of a Buy recommendation. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on BioMarin Pharmaceutical (BMRN). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 14 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.29.

BioMarin Pharmaceutical (BMRN) : Currently there are 14 street experts covering BioMarin Pharmaceutical (BMRN) stock. The most bullish and bearish price target for the stock is $150 and $99 respectively for the short term. The average price target of all the analysts comes to $118.64. The estimated standard deviation from the target is $12.04.


For the current week, the company shares have a recommendation consensus of Buy. Also, Barclays maintains its rating on BioMarin Pharmaceutical (NASDAQ:BMRN). The global brokerage major raises the current price target from $105 per share to $125 per share. Analysts at the Barclays have a current rating of Overweight on the shares. The rating by the firm was issued on August 5, 2016.

BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened at $94.95 and touched an intraday high of $96.23 on Wednesday. During the day, the stock corrected to an intraday low of $93.6, however, the bulls stepped in and pushed the price higher to close in the green at $96.14 with a gain of 0.58% for the day. The total traded volume for the day was 1,475,689. The stock had closed at $95.59 in the previous trading session.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.